Baseline Research Indicates High Interest in Centocor-Ortho Biotech's ... ( EXTON Pa. May 8 /- BioTrends Research...)

Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)

Date:5/8/2009

EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th.

95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales representatives. Two-thirds reported a favorable reaction to SIMPONI and 83% reported a high interest in learning more about the product. Among those familiar with SIMPONI, nearly all were aware of the monthly dosing intervals, but overall the respondents were less familiar with the product's indications and dose delivery forms. Compared to the other biologics indicated for RA, 43% identified SIMPONI as the "easiest to administer/easiest for patients to take" while 26% gave Abbott's HUMIRA(R) top billing for ease of use. The respondents reported that close to 40% of their severe RA patients could be considered candidates for SIMPONI and that the majority of SIMPONI patients would be switched from other biologic agents. Market share projections suggest that SIMPONI will primarily draw from other TNF-inhibitors and 38% of the respondents suggest that they will prescribe the product for their RA patients as soon as it is available.

Surveyed Rheumatologists are also highly aware of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in ACTEMRA compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a greater interest in SIMPONI by a 3:1 margin.

About SIMPONI

Centocor Ortho Biotech, Inc. received FDA approval for SIMPONI(R)'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year

Post Your Comments:

Baseline Research Indicates High Interest in Centocor-Ortho Biotech's ...( EXTON Pa. May 8 /- BioTrends Research...)